In mice with advanced fatty-liver disease, semaglutide lowered body weight and cut the burden of liver cancer, but it did not measurably shrink the scarring in their livers. Adding a second drug built specifically to attack that scarring changed nothing.
That is the result of a mouse study published September 18 in PLoS One ↗ by a team testing whether two drugs that work on different parts of the same disease would add up to more than either alone. They did not.
The setup
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is the fatty-liver condition that tracks with obesity and type 2 diabetes. In its advanced form the liver inflames and scars (fibrosis), and a scarred liver carries a higher risk of hepatocellular carcinoma, the most common form of liver cancer. The drugs that have reached patients so far mostly treat the metabolic drivers upstream. Resmetirom (Rezdiffra), Madrigal Pharmaceuticals' drug and the first the FDA approved for the advanced form in 2024, acts on the thyroid-hormone-receptor beta. GLP-1 receptor agonists like semaglutide, the molecule sold as Ozempic and Wegovy, take weight and blood sugar down.
The problem is that once a liver is already scarred, correcting the metabolism upstream may not undo the damage downstream. So the logic the authors tested is a common one in the field: pair a metabolic drug with a drug that targets the scarring itself. The scarring drug here was rencofilstat (CRV431), an investigational cyclophilin inhibitor from Hepion Pharmaceuticals that has been pitched as antifibrotic, carries FDA Fast Track status for the advanced disease, and holds an orphan-drug designation for liver cancer. On paper, the two drugs cover different bases. The question was whether combining them would stack.
What the mice showed
The team induced advanced disease in C57BL/6J mice with a Western diet, extra sucrose, and chronic exposure to carbon tetrachloride, a liver toxin. They then compared semaglutide alone, rencofilstat alone, and the two together.
Semaglutide alone did real work on two fronts. It reduced body weight, and it decreased the liver-cancer burden, a difference the authors report as strongly significant (Kruskal-Wallis test, p less than 0.0001). That is the piece worth sitting with: the weight-loss drug moved the cancer endpoint.
The scarring is where the story turns. Fibrosis, measured by picrosirius red staining that lights up collagen, did not differ significantly across any of the treatment groups (Welch's analysis of variance, p equals 0.1725). Semaglutide did not reduce it. Rencofilstat did not reduce it. And the combination did not improve collagen deposition over either drug given alone. The rational pairing produced no additive benefit.
Why a null result is the point
The authors frame this as a stage-dependent limit. Advanced disease reflects both the upstream metabolic stress and a downstream, self-sustaining injury response that has taken on a life of its own. Correcting the metabolism, even while also inhibiting a fibrosis pathway, may simply arrive too late to reverse collagen that is already laid down. A combination that looks additive in a slide deck can flatten out in an already-cirrhotic liver.
The caveats are the usual ones for work at this stage, and they are load-bearing. This is one mouse study from a single group, in a toxin-driven model that is not the same disease a human patient has. The paper does not report the number of animals per arm in its abstract, and picrosirius staining is a snapshot, not a functional readout. A null on fibrosis in mice does not close the door on either drug in people. Rencofilstat's own phase 2a data in F2/F3 patients ↗ reported it was safe and well tolerated, which is a different question from whether it adds to a GLP-1 drug.
What the result does is push back on the assumption that GLP-1 benefit extends cleanly to the scarred liver, and on the reflex that two antifibrotic-adjacent drugs are better than one. Here the metabolic drug carried the cancer signal by itself, the scarring did not move, and the combination that was supposed to close the gap did not.
For context on how hard the fibrosis endpoint has been to move with incretin-style drugs, peptidemodel hosts the semaglutide card ↗ against the GLP-1 receptor ↗, and covered a human analysis where a rival drug's liver-scarring benefit mostly did not come from weight loss ↗. The direction of travel keeps pointing at the same hard question: what actually reverses the scar.